| 2025-12-01 |
详情>>
内部人交易：
Vandervoort Adam C等共交易16笔
|
| 2025-10-30 |
详情>>
股本变动：
变动后总股本17747.34万股
|
| 2025-10-30 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-1美元,归母净利润-1.75亿美元,同比去年增长81.61%
|
| 2025-10-29 |
财报披露：
美东时间 2025-10-29 盘后发布财报
|
| 2025-07-30 |
详情>>
业绩披露：
2025年中报每股收益-0.72美元,归母净利润-1.26亿美元,同比去年增长86.33%
|
| 2025-05-01 |
详情>>
业绩披露：
2025年一季报每股收益-0.53美元,归母净利润-9301.2万美元,同比去年增长-13.58%
|
| 2025-04-08 |
股东大会：
将于2025-05-22召开股东大会
会议内容 ▼▲
- 1.To elect nine nominees to serve as directors
2.To conduct an advisory vote to approve our executive compensation (Say-on-Pay)
3.To approve an amendment to the Teladoc Health, Inc. 2023 Incentive Award Plan
4.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for fiscal 2025
5.To transact other business as may properly come before the meeting or any adjournment(s) or postponement(s) of the meeting
|
| 2025-02-27 |
详情>>
业绩披露：
2024年年报每股收益-5.87美元,归母净利润-10.01亿美元,同比去年增长-354.35%
|
| 2025-02-27 |
详情>>
业绩披露：
2022年年报每股收益-84.6美元,归母净利润-136.6亿美元,同比去年增长-3085.58%
|
| 2024-10-31 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-5.61美元,归母净利润-9.53亿美元,同比去年增长-397.62%
|
| 2024-08-01 |
详情>>
业绩披露：
2023年中报每股收益-0.82美元,归母净利润-1.34亿美元,同比去年增长98.63%
|
| 2024-08-01 |
详情>>
业绩披露：
2024年中报每股收益-5.44美元,归母净利润-9.2亿美元,同比去年增长-584.17%
|
| 2024-04-26 |
详情>>
业绩披露：
2024年一季报每股收益-0.49美元,归母净利润-8188.9万美元,同比去年增长-18.29%
|
| 2024-04-09 |
股东大会：
将于2024-05-23召开股东大会
会议内容 ▼▲
- 1.To elect eight nominees to serve as directors
2.To conduct an advisory vote to approve our executive compensation (Say-on-Pay)
3.To conduct an advisory vote to approve the frequency of future advisory votes on the compensation of Teladoc Health’s named executive officers
4.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for fiscal 2024
5.To transact other business as may properly come before the meeting or any adjournment(s) or postponement(s) of the meeting
|
| 2024-02-23 |
详情>>
业绩披露：
2023年年报每股收益-1.34美元,归母净利润-2.2亿美元,同比去年增长98.39%
|
| 2023-10-27 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-1.17美元,归母净利润-1.91亿美元,同比去年增长98.06%
|
| 2023-04-11 |
股东大会：
将于2023-05-25召开股东大会
会议内容 ▼▲
- 1.To elect nine nominees to serve as directors
2.To conduct an advisory vote to approve our executive compensation (Say-on-Pay)
3.To approve the Teladoc Health, Inc. 2023 Incentive Award Plan
4.To approve an amendment to the Teladoc Health, Inc. 2015 Employee Stock Purchase Plan
5.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for fiscal 2023
6.Stockholder proposal, if properly presented at the Annual Meeting
7.To transact other business as may properly come before the meeting or any adjournment(s) or postponement(s) of the meeting
|
| 2023-01-24 |
复牌提示：
2023-01-24 09:30:15 停牌，复牌日期 2023-01-24 09:35:59
|
| 2022-04-12 |
股东大会：
将于2022-05-26召开股东大会
会议内容 ▼▲
- 1.To elect 10 nominees to serve as directors
2.To conduct an advisory vote to approve our executive compensation (Say-on-Pay)
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for fiscal 2022
4.To approve an amendment to our Certificate of Incorporation to permit holders of at least 15% net long ownership in voting power of our outstanding capital stock to call special meetings
5.To transact other business as may properly come before the meeting or any adjournment(s) or postponement(s) of the meeting
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-07 |
股东大会：
将于2021-05-17召开股东大会
会议内容 ▼▲
- 1.electing the director-nominees named in the proxy statement;
2.approving, on an advisory basis, the compensation of Teladoc Health’s named executive officers;
3.ratifying the appointment of Ernst & Young LLP as Teladoc Health’s independent registered public accounting firm for the fiscal year ending December 31, 2021;
4.transacting such other business as may properly come before the meeting or any postponement(s) or adjournment(s) thereof.
|
| 2020-09-15 |
股东大会：
将于2020-10-29召开股东大会
会议内容 ▼▲
- 1.to approve the issuance of shares of Teladoc common stock to the stockholders of Livongo Health, Inc., which is referred to as Livongo, pursuant to the Agreement and Plan of Merger, dated as of August 5, 2020 (as it may be amended from time to time), which is referred to as the merger agreement, by and among Teladoc, Livongo and Tempranillo Merger Sub, Inc., a wholly-owned subsidiary of Teladoc, which proposal is referred to as the Teladoc share issuance proposal;
2.to adopt an amendment to the certificate of incorporation of Teladoc, which amendment is referred to as the charter amendment and which proposal is referred to as the Teladoc charter amendment proposal;
3.to approve the adjournment of the Teladoc stockholder meeting to solicit additional proxies if there are not sufficient votes at the time of the Teladoc stockholder meeting to approve the Teladoc share issuance proposal and the Teladoc charter amendment proposal or to ensure that any supplement or amendment to the accompanying joint proxy statement/prospectus is timely provided to Teladoc stockholders, which is referred to as the Teladoc adjournment proposal.
|
| 2020-04-14 |
股东大会：
将于2020-05-28召开股东大会
会议内容 ▼▲
- 1.electing the director-nominees named in the proxy statement;
2.approving, on an advisory basis, the compensation of Teladoc Health’s named executive officers;
3.ratifying the appointment of Ernst & Young LLP as Teladoc Health’s independent registered public accounting firm for the fiscal year ending December 31, 2020;
4.transacting such other business as may properly come before the meeting or any postponement(s) or adjournment(s) thereof.
|
| 2019-04-19 |
股东大会：
将于2019-05-30召开股东大会
会议内容 ▼▲
- 1.electing the director-nominees named in the proxy statement;
2.approving, on an advisory basis, the compensation of Teladoc Health's named executive officers;
3.ratifying the appointment of Ernst & Young LLP as Teladoc Health's independent registered public accounting firm for the fiscal year ending December 31, 2019;
4.transacting such other business as may properly come before the meeting or any postponement(s) or adjournment(s) thereof.
|
| 2018-04-20 |
股东大会：
将于2018-05-31召开股东大会
会议内容 ▼▲
- 1.approving an amendment to Teladoc’s sixth amended and restated certificate of incorporation to increase the total authorized shares of Teladoc common stock from 100,000,000 shares to 150,000,000 shares;
2.electing the director-nominees named in the proxy statement;
3.approving, on an advisory basis, the compensation of Teladoc’s named executive officers;
4.approving, on an advisory basis, the frequency of future advisory votes on the compensation of Teladoc’s named executive officers;
5.ratifying the appointment of Ernst & Young LLP as Teladoc’s independent registered public accounting firm for the fiscal year ending December 31, 2018; 6.transacting such other business as may properly come before the meeting or any postponement(s) or adjournment(s) thereof.
|
| 2017-04-06 |
股东大会：
将于2017-05-25召开股东大会
会议内容 ▼▲
- 1.approving amendments to Teladoc’s certificate of incorporation (the “Certificate”) to (a) increase the total authorized shares of Teladoc common stock from 75,000,000 shares to 100,000,000 shares; (b) declassify Teladoc’s Board of Directors; (c) eliminate the supermajority voting requirement for stockholders to remove a director from office; (d) eliminate the supermajority voting requirement for amendments to certain provisions of the Certificate; and (e) eliminate the supermajority voting requirement for stockholders to amend Teladoc’s bylaws;
2.electing the director-nominees named in the proxy statement;
3.approving the amendment and restatement of the Teladoc, Inc. 2015 Incentive Award Plan;
4.ratifying the appointment of Ernst & Young LLP as Teladoc’s independent registered public accounting firm for the fiscal year ending December 31, 2017;
5.such other business as may properly come before the meeting or any postponement(s) or adjournment(s) thereof.
|
| 2016-04-15 |
股东大会：
将于2016-05-26召开股东大会
会议内容 ▼▲
- 1.elect three directors, each for a term of three years;
2.ratify the appointment of Ernst & Young LLP as Teladoc’s independent registered public accounting firm for the fiscal year ending December 31, 2016;
3.transact any other business that may properly come before the meeting.
|